
European Journal of Medicinal Chemistry (2021)
Update date:2022-08-05
Topics:
Laura, Medve
Ronan, Gealageas
Vy, Lam Bao
Valentin, Guillaume
Omar, Castillo-Aguilera
Virgyl, Camberlein
Piveteau, Catherine
Melissa, Rosell
Charlotte, Fleau
Sandrine, Warenghem
Julie, Charton
Julie, Dumont-Ryckembusch
Damien, Bosc
Florence, Leroux
Peter, van Endert
Benoit, Deprez
Rebecca, Deprez-Poulain
Endoplasmic reticulum aminopeptidase 2, ERAP2, is an emerging pharmacological target in cancer immunotherapy and control of autoinflammatory diseases, as it is involved in antigen processing. It has been linked to the risk of development of spondyloarthritis, and it associates with the immune infiltration of tumours and strongly predicts the overall survival for patients receiving check-point inhibitor therapy. While some selective inhibitors of its homolog ERAP1 are available, no selective modulator of ERAP2 has been disclosed so far. In order to identify such compounds, we screened an in-house focused library of 1920 compounds designed to target metalloenzymes. Structure-Activity Relationships and docking around two hits led to the discovery of selective inhibitors of ERAP2. Amid those, some bind to yet untapped amino-acids in the S1 pocket. Importantly, we disclose also the first activator of small substrates hydrolysis by ERAP2. Inhibitors and activators identified in this study could serve as useful starting points for optimization.
View MoreTianjin Dongchang Fine Chemical Industry Co., Ltd.
Contact:+86-22-29894595
Address:Economic Developing Zone, Ji County, Tianjin, China
Contact:+86-134-5286-9121
Address:Add: Wing Tuck Commercial Centre, 177-183 Wing Lok Street, Hong Kong,
Antaeus Bio-technology Co., LTD(expird)
Contact:021-31252569
Address:shanghai pudong
Contact:+86-021-50792271
Address:Building 24A, 300 Chuantu Road, Chuansha, Pudong new area, Shanghai, China, 201202
website:http://www.gbxfsilicones.com/
Contact:86-25-68900673
Address:He Country Provincial Fine Chemical Industrial Park of Chaohu city,Anhui province,China
Doi:10.1016/S0040-4039(00)95583-7
(1987)Doi:10.1021/jo900428j
(2009)Doi:10.1021/acs.oprd.9b00178
(2019)Doi:10.1016/S0040-4039(00)96439-6
(1987)Doi:10.1080/00397910802531955
(2009)Doi:10.1002/hlca.200800343
(2009)